Department of Dermatology, UHC "Mother Teresa", Tirana, Albania.
Department of Dermatology, University of Medicine, Tirana, Albania.
Dermatol Ther. 2019 Jul;32(4):e12936. doi: 10.1111/dth.12936. Epub 2019 Apr 25.
Psoriasis is a chronic, immune-mediated skin disease that also has systemic manifestations. Biologic preparates: Adalimumab, Etanercept, and Infliximab are licensed for psoriasis vulgaris treatment in Albania. To compare the efficacy of biologic therapies used for psoriasis based in our experience. A cohort prospective study during the years 2016-2018 at UHC "Mother Teresa" Tirana. In the study took place 78 patient diagnosed with psoriasis and treated with biologic therapies. Psoriasis Area Severity Index (PASI) 50 and PASI 75 index were the parameters of response outcomes. PASI 50 was achieved for 6.8, 7.02, and 7.2 weeks in patients with Etanercept, Adalimumab, and Infliximab respectively and PASI 75 for 12.8, 11.4, and 11.42 weeks. X2 = 0.076, p > .05, nonsignificant difference. PASI 50 was achieved in 27.2% of subject treated with Etanercept, 67.4% Adalimumab, and 55.5% with Infliximab for the weeks mentioned above. Meanwhile PASI 75 was achieved in 45.4% of subject treated with Etanercept, 61.7% Adalimumab, and 25% with Infliximab. X2 = 15.28, p < .05, significant difference. Biologics have revolutionized the treatment of psoriasis. To select the most appropriate agent for patient, should be considered multiple factors including adverse effects, tolerance, patient preference, cost, and mode of administration.
银屑病是一种慢性、免疫介导的皮肤疾病，也有全身表现。生物制剂：阿达木单抗、依那西普和英夫利昔单抗在阿尔巴尼亚被批准用于治疗寻常型银屑病。为了比较我们经验中用于银屑病的生物疗法的疗效。这是一项在 2016 年至 2018 年期间在 UHC“Mother Teresa”地拉那进行的队列前瞻性研究。该研究共纳入 78 例诊断为银屑病并接受生物疗法治疗的患者。银屑病面积严重程度指数（PASI）50 和 PASI 75 指数是反应结果的参数。依那西普、阿达木单抗和英夫利昔单抗治疗的患者分别在第 6.8、7.02 和 7.2 周达到 PASI 50，在第 12.8、11.4 和 11.42 周达到 PASI 75。X2=0.076，p＞0.05，无显著差异。在上述时间点，用依那西普治疗的患者中有 27.2%、用阿达木单抗治疗的患者中有 67.4%、用英夫利昔单抗治疗的患者中有 55.5%达到 PASI 50。同时，在上述时间点，用依那西普治疗的患者中有 45.4%、用阿达木单抗治疗的患者中有 61.7%、用英夫利昔单抗治疗的患者中有 25%达到 PASI 75。X2=15.28，p＜0.05，有显著差异。生物制剂彻底改变了银屑病的治疗方法。为了为患者选择最合适的药物，应考虑多种因素，包括不良反应、耐受性、患者偏好、成本和给药方式。
